Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?

Canadian Family Physician

Volumn 48, Issue SEPT., 2002, Pages 1449-1451

  Kvern, Brent ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELEBRIX; CELECOXIB; DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ANTICOAGULATION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; METHODOLOGY; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAMPLE SIZE; SIDE EFFECT; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS;

EID: 0036751550     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
2. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-71.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343: 1520-8.
4. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al, for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000;284:1247-55.